Document Detail


Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer.
MedLine Citation:
PMID:  20554995     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: The aim of this study was to test for the influence of ascorbic acid on tumorigenicity and metastases of implanted PAIII prostate cancer adenocarcinoma cells in syngeneic LW rats. MATERIALS AND METHODS: Hormone-refractory prostate cancer PAIII cells were implanted subcutaneously into immunologically intact, Lobund-Wistar (LW) rats. Intraperitoneal pharmacological doses of ascorbic acid were administered each day for the ensuing 30 days. On the 40th day, animals were sacrificed. Local tumor weights were measured, and metastases were counted. RESULTS: At the end of the 40 day experimental period, the primary tumors were found to be significantly reduced in weight (p=0.026). In addition, sub-pleural lung metastases were even more profoundly reduced in number and size (p=0.009). Grossly enlarged ipsilateral lymph node metastases declined from 7 of 15 rats to 1 of 15 rats. CONCLUSION: Pharmacological doses of ascorbic acid suppress tumor growth and metastases in hormone-refractory prostate cancer.
Authors:
Harvey B Pollard; Mark A Levine; Ofer Eidelman; Morris Pollard
Related Documents :
6953805 - Brain cancer: issues and dilemmas.
19830225 - Duodenal metastasis from male breast cancer: a case report and review of the literature.
24041225 - Breast cancer receptor status and stage at diagnosis in over 1200 consecutive public ho...
23725885 - Efficient mapping and geographic disparities in breast cancer mortality at the county-l...
23811005 - Therapeutic efficacy and molecular mechanisms of snake (walterinnesia aegyptia) venom-l...
19629725 - Chemokine ccl2/mcp-1 negatively regulates metastasis in a highly bone marrow-metastatic...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  In vivo (Athens, Greece)     Volume:  24     ISSN:  0258-851X     ISO Abbreviation:  In Vivo     Publication Date:    2010 May-Jun
Date Detail:
Created Date:  2010-06-17     Completed Date:  2010-08-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8806809     Medline TA:  In Vivo     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  249-55     Citation Subset:  IM    
Affiliation:
Department of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, USUHS, Bethesda, MD 20814, USA. hpollard@usuhs.mil
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / drug therapy*,  secondary
Animals
Antioxidants / pharmacology*
Ascorbic Acid / pharmacology*
Body Weight
Intercellular Signaling Peptides and Proteins / metabolism
Lung Neoplasms / drug therapy*,  secondary
Lymphatic Metastasis
Male
Neoplasm Transplantation
Prostatic Neoplasms / drug therapy*,  pathology
ROC Curve
Rats
Rats, Wistar
Grant Support
ID/Acronym/Agency:
CA 17559/CA/NCI NIH HHS; N01-HV-28187/HV/NHLBI NIH HHS; RR00294/RR/NCRR NIH HHS; Z01 DK053212-02/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Antioxidants; 0/Intercellular Signaling Peptides and Proteins; 50-81-7/Ascorbic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vertebral osteomyelitis.
Next Document:  A Non-traumatic Staphylococcus aureus Osteomyelitis Model in Pigs.